DrugPatentWatch Database Preview
OXBRYTA Drug Profile
» See Plans and Pricing
Which patents cover Oxbryta, and what generic alternatives are available?
Oxbryta is a drug marketed by Global Blood Theraps and is included in one NDA. There are eight patents protecting this drug.
This drug has one hundred and eighty-nine patent family members in thirty-two countries.
The generic ingredient in OXBRYTA is voxelotor. Additional details are available on the voxelotor profile page.
DrugPatentWatch® Generic Entry Outlook for Oxbryta
Oxbryta will be eligible for patent challenges on November 25, 2023. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be October 12, 2037. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for OXBRYTA
| International Patents: | 189 |
| US Patents: | 8 |
| Applicants: | 1 |
| NDAs: | 1 |
| Bulk Api Vendors: | 34 |
| Clinical Trials: | 1 |
| Patent Applications: | 57 |
| Drug Prices: | Drug price information for OXBRYTA |
| What excipients (inactive ingredients) are in OXBRYTA? | OXBRYTA excipients list |
| DailyMed Link: | OXBRYTA at DailyMed |
DrugPatentWatch® Estimated Generic Entry Opportunity Date for OXBRYTA
Generic Entry Date for OXBRYTA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for OXBRYTA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Global Blood Therapeutics | Phase 4 |
US Patents and Regulatory Information for OXBRYTA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Global Blood Theraps | OXBRYTA | voxelotor | TABLET;ORAL | 213137-001 | Nov 25, 2019 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Global Blood Theraps | OXBRYTA | voxelotor | TABLET;ORAL | 213137-001 | Nov 25, 2019 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Global Blood Theraps | OXBRYTA | voxelotor | TABLET;ORAL | 213137-001 | Nov 25, 2019 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Global Blood Theraps | OXBRYTA | voxelotor | TABLET;ORAL | 213137-001 | Nov 25, 2019 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Global Blood Theraps | OXBRYTA | voxelotor | TABLET;ORAL | 213137-001 | Nov 25, 2019 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Global Blood Theraps | OXBRYTA | voxelotor | TABLET;ORAL | 213137-001 | Nov 25, 2019 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for OXBRYTA
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Taiwan | I670265 | Start Trial |
| Peru | 20151907 | Start Trial |
| Mexico | 2015011445 | Start Trial |
| Denmark | 3141542 | Start Trial |
| Spain | 2811129 | Start Trial |
| Taiwan | 201938550 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
